Related references
Note: Only part of the references are listed.Desmoplastic Melanoma: Is There a Role for Sentinel Lymph Node Biopsy?
Dale Han et al.
ANNALS OF SURGICAL ONCOLOGY (2013)
Clinicopathologic Predictors of Sentinel Lymph Node Metastasis in Thin Melanoma
Dale Han et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo
Christian Posch et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Preoperative Ultrasound is Not Useful for Identifying Nodal Metastasis in Melanoma Patients Undergoing Sentinel Node Biopsy: Preoperative Ultrasound in Clinically Node-Negative Melanoma
Christy Y. Chai et al.
ANNALS OF SURGICAL ONCOLOGY (2012)
Sentinel Node Biopsy is Indicated for Thin Melanomas ≥0.76 mm
Dale Han et al.
ANNALS OF SURGICAL ONCOLOGY (2012)
Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma
John M. Kirkwood et al.
CLINICAL CANCER RESEARCH (2012)
Sunitinib Therapy for Melanoma Patients with KIT Mutations
David R. Minor et al.
CLINICAL CANCER RESEARCH (2012)
Melanoma prevention: are we doing enough? A Canadian perspective
A. M. Joshua
CURRENT ONCOLOGY (2012)
Sentinel Lymph Node Biopsy for Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Joint Clinical Practice Guideline
Sandra L. Wong et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Correlation of NRAS Mutations With Clinical Response to High-dose IL-2 in Patients With Advanced Melanoma
Richard W. Joseph et al.
JOURNAL OF IMMUNOTHERAPY (2012)
Surgical margins for melanoma in situ
Joy H. Kunishige et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2012)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild et al.
LANCET (2012)
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Survival in BRAF V600-Mutant Advanced Melanoma Treated with Vemurafenib
Jeffrey A. Sosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
Fei Su et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma
Evan M. Hersh et al.
INVESTIGATIONAL NEW DRUGS (2011)
KIT as a Therapeutic Target in Metastatic Melanoma
Richard D. Carvajal et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring c-Kit Mutation or Amplification
Jun Guo et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial
Peter Gillgren et al.
LANCET (2011)
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikos I. Poulikakos et al.
NATURE (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT
D. Handolias et al.
BRITISH JOURNAL OF CANCER (2010)
Long-term outcome of hyperthermic isolated limb perfusion (HILP) in the treatment of locoregionally metastasised malignant melanoma of the extremities
Cedric E. Boesch et al.
INTERNATIONAL JOURNAL OF HYPERTHERMIA (2010)
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Gideon Bollag et al.
NATURE (2010)
Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian et al.
NATURE (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner
Eric W. Joseph et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Whole brain radiotherapy plus stereotactic radiosurgery (WBRT plus SRS) versus surgery plus whole brain radiotherapy (OP plus WBRT) for 1-3 brain metastases: Results of a matched pair analysis
Dirk Rades et al.
EUROPEAN JOURNAL OF CANCER (2009)
PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4(+)CD25(Hi) regulatory T cells
Wenshi Wang et al.
INTERNATIONAL IMMUNOLOGY (2009)
Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma
Axel Hauschild et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Final Version of 2009 AJCC Melanoma Staging and Classification
Charles M. Balch et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A Multi-Institutional Experience of Isolated Limb Infusion: Defining Response and Toxicity in the US
Georgia M. Beasley et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2009)
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi
Catherine D. Van Raamsdonk et al.
NATURE (2009)
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers
Alex A. Adjei et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
James Tsai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
The utility of ultrasound in patients with melanoma
Roger F. Uren et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2007)
Role of radiologic Imaging at the time of initial diagnosis of stage T1b-T3b melanoma
Molly Yancovitz et al.
CANCER (2007)
Sentinel-node biopsy or nodal observation in melanoma
Donald L. Morton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group trial Z0020
Wendy R. Cornett et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
MC1R germline variants confer risk for BRAF-mutant melanoma
Maria Teresa Landi et al.
SCIENCE (2006)
Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases - A randomized controlled trial
Hidefumi Aoyama et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Utility of preoperative [(18)]F fluorodeoxyglucose-positron emission tomography scanning in high-risk melanoma patients
MS Brady et al.
ANNALS OF SURGICAL ONCOLOGY (2006)
Futility of fluorodeoxyglucose F 18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma
PB Clark et al.
ARCHIVES OF SURGERY (2006)
Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: A phase I/II study
AV Maker et al.
ANNALS OF SURGICAL ONCOLOGY (2005)
Distinct sets of genetic alterations in melanoma
JA Curtin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4
P Attia et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma
JD Wagner et al.
CANCER (2005)
Mutant V599EB-RAF regulates growth and vascular development of malignant melanoma tumors
A Sharma et al.
CANCER RESEARCH (2005)
A pooled analysis of Eastern Cooperative Oncology Group and Intergroup trials of adjuvant high-dose interferon for melanoma
JM Kirkwood et al.
CLINICAL CANCER RESEARCH (2004)
Excision margins in high-risk malignant melanoma
JM Thomas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma
H Tsao et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2004)
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
GQ Phan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
FS Hodi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick) -: Long-term results of a large European multicentric phase III study
D Khayat et al.
CANCER (2003)
A comparison of surgical resection and stereotactic radiosurgery in the treatment of solitary brain metastases
BP O'Neill et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2003)
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Y Iwai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Frequency of nonsentinel lymph node metastasis in melanoma
KM McMasters et al.
ANNALS OF SURGICAL ONCOLOGY (2002)
Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (>= 4 mm) primary melanoma
JE Gershenwald et al.
ANNALS OF SURGICAL ONCOLOGY (2000)
Share Paper
